Inflammatory markers in stable heart failure and their relationship with functional class

References 

1. Torre-Amione G. Inmune activation in chronic heart failure. Am J Cardiol. 2005;96:3C–8C
2. Anderson MR. Prog Pediatr Cardiol. 2000;11:219–230
   • Abstract
   • Full Text
   • Full-Text PDF (1095 KB)
   • CrossRef
3. Allain P, Olivier E, Le Bouil A, et al. Increase of sialic acid concentration in the plasma of patients with coronary disease. Presse Med. 1996;25:96–98
   • MEDLINE
4. Coppola G, Rizzo M, Abrignani MG, et al. Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two month follow-up study. Ital Heart J. 2005;6:315–322
   • MEDLINE
5. Lang R, Bierig M, Devereux R, et al. Recommendations for chamber quantification: a report from the Amerian Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European society of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463
   • Full Text
   • Full-Text PDF (1012 KB)
   • CrossRef
6. Reganon E, Martínez-Sales V, Vila V, et al. Relationship between fibrinogen protein and fibrinogen function in post-myocardial infarction patients. Thromb Res. 2001;105:1–7
   • Full Text
   • Full-Text PDF (32 KB)
   • CrossRef
7. Sola S, Mir M, Rajagoplan S, Helmy T, Tandom N, Khan R. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail. 2005;11:607–612
   • Abstract
   • Full Text
   • Full-Text PDF (121 KB)
   • CrossRef
8. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure. Circulation. 2003;107:1991–1997
   • CrossRef
9. Farquharson C, Butler R, Hill A, Belch J, Struthers A. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221–226
   • CrossRef
10. Lip G, Lip H, Pearce LA, Chin BSP, Conway DSG, Hart RG. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvular atrial fibrilation. Heart. 2005;91:759–763
11. Rodríguez-Reyna TS, Arrieta O, Castillo-Martínez L, et al. Tumour necrosis factor alpha and troponin T as a predictor of poor prognosis in patients with stable Heart failure. Clin Invest Med. 2005;28:23–29
    • MEDLINE
12. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–938
    • Abstract
    • Full Text
    • Full-Text PDF (194 KB)
    • CrossRef
13. Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J heart Fail. 2002;4:331–336
    • MEDLINE
    • CrossRef
14. Arnau Vives MA, Rueda Soriano J, Martínez Dolz L, et al. Valor pronóstico del fibrinógeno en pacientes ingresados con sospecha de angina inestable o infarto de miocardio sin onda Q. Rev Esp Cardiol. 2002;55:622–630
    • MEDLINE
15. Cugno M, Mari D, Meroni PL, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and succesful heart transplantation. Br J Haematol. 2004;126:85–92
    • MEDLINE
    • CrossRef
16. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1789–1809
17. Crook JR, Goldman JH, Dalziel M, et al. Increased ventricular sialylation in patients with heart failure secondary to ischemic heart disease. Clin Cardiol. 1997;20:455–458
    • MEDLINE
    • CrossRef
18. Smith S, Anderson J, Cannon R, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Circulation. 2004;110:550–553
19. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:449–511
20. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005;112:1289–1295
    • CrossRef
21. Smolen JS, Han C, van der Heijde , et al. Infliximab treatment maintains employability in patients with early rheumatoid artritis. Arthritis Rheum. 2006;54:716–722
    • MEDLINE
    • CrossRef
22. Finckh A, Simard JF, Durvea J, et al. The effectivness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid artritis: a population-based study. Arthritis Rheum. 2006;54:54–59
    • MEDLINE
    • CrossRef
23. Cheng ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF therapy against congestive heart failure. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–3140
    • CrossRef
24. Kosar F, Aksov Y, Ozguntekin G, Ozerol I, Varol E. Relationship between cytokines and tumor marker in patients with chronic heart failure. Eur J Heart Fail. 2006;8:270–274
    • MEDLINE
25. Herrera Garza H, Herrera Garza JL, Rodríguez González H, Treviño Treviño A, Ibarra Flores M, Torre Amione G. Importancia del factor de necrosis tumoral-alfa en la patogénesis de la insuficiencia cardíaca. Rev Esp Cardiol. 2002;55:61–66
    • MEDLINE